Puma Biotechnology, Inc.
$7.05-$0.07 (-1.0%)
Last close · Data as of Nov 20, 2026
- Market cap
- $356.8M
- P/E
- 11.5x
- EV / EBITDA
- 6.7x
- Revenue
- $228.4M
- Net margin
- 13.6%
- ROCE
- 27.6%
Price chart
Technical chartScreen technicals →+45.7% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -34.5%
- 3M
- -22.6%
- 6M
- +0.9%
- 1Y
- +45.7%
- 5Y
- +106.1%
52-week range
Day change -$0.07 (-1.0%) from $7.12 to $7.05 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in PBYI, bought on each weekday since 2021.
News & filings
What Puma Biotechnology filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockStrengthReturn on capital employed of 27.6%.
Concerns (1)
- Revenue grew 0.0% a year over three years.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
Read moreShow less
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks. The company has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
- Sector
- Healthcare
- Shares outstanding
- 50.2M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $356.8M
- P/E
- 11.5x
- P/B
- 2.7x
- EV / EBITDA
- 6.7x
- EV / Sales
- 1.6x
- P/S
- 1.6x
- 52-week high
- $11.26
- 52-week low
- $4.84
Profitability
- Operating margin
- 16.3%
- Net margin
- 13.6%
- EBITDA margin
- 23.4%
- ROE
- 23.9%
- ROCE
- 27.6%
- ROIC
- 28.5%
- ROA
- 14.4%
- Asset turnover
- 1.06
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $228.4M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -0.9%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 0.0%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 2.8%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $41.7M
Solvency
- Current ratio
- 2.00
- Debt / Equity
- 0.22
- Debt / Assets
- 0.13
- CFO / Net profit
- 1.34
- Cash / Market cap
- 8.3%
Where the revenue went
Of every $100 of FY2025 revenue, $14 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $58.2M |
| Revenue | Gross profit | $170.2M |
| Gross profit | Operating expenses | $132.9M |
| Gross profit | Operating income | $37.3M |
| Operating income | Pretax income | $35.8M |
| Operating income | Interest and other expense | $1.5M |
| Pretax income | Tax and other | $4.7M |
| Pretax income | Net income | $31.1M |
Revenue and net profit
Revenue fell 0.9% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $228.0M | $2.0k |
| FY2023 | $235.6M | $21.6M |
| FY2024 | $230.5M | $30.3M |
| FY2025 | $228.4M | $31.1M |
Cash flows
FY2025: $41.8M from operations, $41.7M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -$15.8M | -$22.8M |
| FY2023 | $27.0M | $14.4M |
| FY2024 | $38.9M | $38.9M |
| FY2025 | $41.8M | $41.7M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $228.4M-0.9%1Y
- EBITDA
- $53.3M+11.0%1Y
- Net profit
- $31.1M+2.8%1Y
- Cash from operations
- $41.8M+7.4%1Y
- Free cash flow
- $41.7M+7.4%1Y
- Revenue CAGR, 3Y
- 0.0%
- Net profit CAGR, 3Y
- 2396.3%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $228.4M | $53.3M | $31.1M | $41.7M | 23.9% | -0.9% | +2.8% |
Monthly returns
Month-by-month returns of PBYI across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $216.3M |
| Current assets | $162.7M |
| Non-current assets | $53.6M |
| Liabilities | $86.0M |
| Current liabilities | $81.3M |
| Non-current liabilities | $4.7M |
| Equity | $130.3M |
| Paid-in capital | $1.4B |
| Retained earnings | -$1.3B |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; PBYI highlighted.
P/E against peers
PBYI trades at 11.5x earnings against a peer median of -2.2x.
Not shown (no positive earnings and no EV / Sales): Perspective Therapeutics, Inc., Atea Pharmaceuticals, Inc., Greenwich LifeSciences, Inc., Larimar Therapeutics, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Puma Biotechnology, Inc.PBYIthis company | $356.8M | 11.5x | 2.7x | 23.9% | 6.7x |
| Delcath Systems, Inc.DCTH | $372.5M | 138.0x | 3.3x | 2.4% | 327.0x |
| Perspective Therapeutics, Inc.CATX | $370.7M | -3.6x | 1.8x | -49.8% | -3.4x |
| REGENXBIO Inc.RGNX | $355.7M | -1.8x | 3.5x | -188.7% | -3.0x |
| Atea Pharmaceuticals, Inc.AVIR | $353.7M | -2.2x | 1.3x | -57.5% | -1.4x |
| Greenwich LifeSciences, Inc.GLSI | $347.1M | -22.0x | 137.0x | -623.1% | — |
| Larimar Therapeutics, Inc.LRMR | $341.8M | — | 4.4x | -212.2% | — |
| Enanta Pharmaceuticals, Inc.ENTA | $341.1M | -4.2x | 5.3x | -126.5% | -5.1x |
| Verastem, Inc.VSTM | $339.2M | -1.6x | 5.9x | -366.2% | -1.1x |
| Peer median | — | -2.2x | 3.9x | -157.6% | -2.2x |
Year-to-date ROI
PBYI since 1 January, against earlier years.
Historical volatility
PBYI's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 13.5% |
| FY2023 | 13.9% |
| FY2024 | 13.4% |
| FY2025 | 16.3% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $228.4M |
| Cost of revenueCost Of Revenue | $58.2M |
| Gross profitGross Profit | $170.2M |
| Operating expensesOperating Expense | $132.9M |
| Research and developmentResearch And Development | $62.1M |
| Selling, general and administrativeSelling General And Administration | $71.2M |
| Provision for doubtful accountsProvision For Doubtful Accounts | -$360.0k |
| Total expensesTotal Expenses | $191.1M |
| Operating incomeOperating Income | $37.3M |
| Interest and other | |
| Pretax incomePretax Income | $35.8M |
| TaxTax Provision | $4.7M |
| Net incomeNet Income | $31.1M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $216.3M |
| Current assetsCurrent Assets | $162.7M |
| Non-current assetsTotal Non Current Assets | $53.6M |
| LiabilitiesTotal Liabilities Net Minority Interest | $86.0M |
| Current liabilitiesCurrent Liabilities | $81.3M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $4.7M |
| EquityTotal Equity Gross Minority Interest | $130.3M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $41.8M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $41.8M |
| Net income, continuing operationsNet Income From Continuing Operations | $31.1M |
| Depreciation and amortisationDepreciation And Amortization | $10.9M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $10.9M |
| Stock-based compensationStock Based Compensation | $6.9M |
| Deferred taxDeferred Tax | $3.2M |
| Deferred income taxDeferred Income Tax | $3.2M |
| Operating gains and lossesOperating Gains Losses | $0.00 |
| Gain loss on sale of PP&EGain Loss On Sale Of PPE | $0.00 |
| Asset impairmentAsset Impairment Charge | $0.00 |
| Provision and write off of assetsProvisionand Write Offof Assets | -$360.0k |
| Change in working capitalChange In Working Capital | -$10.1M |
| Other non-cash itemsOther Non Cash Items | — |
| Investing cash flowInvesting Cash Flow | -$36.2M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$36.2M |
| Capital expenditureCapital Expenditure | -$70.0k |
| Purchase of PP&EPurchase Of PPE | -$70.0k |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$70.0k |
| Purchase of investmentsPurchase Of Investment | -$108.1M |
| Sale of investmentsSale Of Investment | $72.0M |
| Net investment purchases and salesNet Investment Purchase And Sale | -$36.1M |
| Purchase of intangiblesPurchase Of Intangibles | $0.00 |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | $0.00 |
| Financing cash flowFinancing Cash Flow | -$45.2M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$45.2M |
| Debt issuedIssuance Of Debt | — |
| Debt repaidRepayment Of Debt | -$44.4M |
| Net debt issuedNet Issuance Payments Of Debt | -$44.4M |
| Long-term debt issuedLong Term Debt Issuance | — |
| Long-term debt repaidLong Term Debt Payments | -$44.4M |
| Net long-term debt issuedNet Long Term Debt Issuance | -$44.4M |
| Shares issuedIssuance Of Capital Stock | — |
| Common stock issuedCommon Stock Issuance | — |
| Net common stock issuedNet Common Stock Issuance | — |
| Stock options exercisedProceeds From Stock Option Exercised | $130.0k |
| Other financing chargesNet Other Financing Charges | -$890.0k |
| Change in cashChanges In Cash | -$39.6M |
| Cash at the start of the yearBeginning Cash Position | $71.3M |
| Cash at the end of the yearEnd Cash Position | $31.7M |
| Free cash flowFree Cash Flow | $41.7M |
| Supplemental |
Learn while you research
Academy chapters picked for Puma Biotechnology, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Value InvestingA P/E of 11.5 could be a value opportunity, or a value trap. Know the difference.7 min read
- 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read